

## DECLARATION

As below named inventors, we hereby declare that:

Our residence, post office address and citizenship are as stated below next to our names.

The below named inventors are the original, first and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled **INTERFERON-GAMMA-BINDING MOLECULES FOR TREATING SEPTIC SHOCK, CACHEXIA, IMMUNE DISEASES AND SKIN DISORDERS**, the specification of which was filed as PCT International Application No. PCT/EP98/05165 on August 14, 1998.

We hereby state that we have reviewed and understand the contents of the above identified specification, including the claims.

We acknowledge the duty to disclose to the Patent and Trademark Office all information known to us to be material to patentability of the subject matter claimed in this application, as "materiality" is defined in Title 37, Code of Federal Regulations, § 1.56.

We hereby claim foreign priority benefits under Title 35, United States Code, § 119 (a)-(d) of any foreign application(s) for patent listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

<u>PRIOR FOREIGN APPLICATION(S)</u>			<u>Priority Claimed</u>
<u>97870122.5</u>	<u>Europe</u>	<u>18 August 1997</u>	<u>Yes</u>
(Number)	(Country)	(Date Filed)	
<u>98870139.7</u>	<u>Europe</u>	<u>18 June 1998</u>	<u>Yes</u>
(Number)	(Country)	(Date Filed)	

We hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, we acknowledge the duty to disclose all information known to me to be material to patentability of the subject matter claimed in this application, as "materiality" is defined in Title 37, Code of Federal Regulations, § 1.56, which become available between the filing date of the prior application and the national or PCT international filing date of this application.


<u>PCT/EP98/05165</u>	<u>14 August 1998</u>
(International Application No.)	(International Filing Date)


We hereby direct that all correspondence and telephone calls be addressed to:

Patricia A. Kammerer  
Arnold, White & Durkee  
P. O. Box 4433  
Houston, Texas 77210-4433  
(713) 787-1438

attorneys for the assignee of this application.

WE HEREBY DECLARE THAT ALL STATEMENTS MADE OF OUR OWN KNOWLEDGE ARE TRUE AND THAT ALL STATEMENTS MADE ON INFORMATION AND BELIEF ARE BELIEVED TO BE TRUE; AND FURTHER THAT THESE STATEMENTS WERE MADE WITH THE KNOWLEDGE THAT WILLFUL FALSE STATEMENTS AND THE LIKE SO MADE ARE PUNISHABLE BY FINE OR IMPRISONMENT, OR BOTH, UNDER SECTION 1001 OF TITLE 18 OF THE UNITED STATES CODE AND THAT SUCH WILLFUL FALSE STATEMENTS MAY JEOPARDIZE THE VALIDITY OF THE APPLICATION OR ANY PATENT ISSUED THEREON.

Inventor's Full Name	MARIE-ANGE	BUYSE
Inventor's Signature		
Date: 1 feb '00		Country of Citizenship: BELGIUM
Residence Address	Burg. E. Ronsestraat 23 B-9820 Merelbeke BELGIUM	
Post Office Address, if different from above	same as above	

Inventor's Full Name	ERWIN	SABLON
Inventor's Signature		
Date: 4 feb '00		Country of Citizenship: BELGIUM
Residence Address	Robbroeklaan 1A B-1785 Merchtem BELGIUM	
Post Office Address, if different from above	same as above	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
MARIE-ANGE BUYSE  
ERWIN SABLON

Group Art Unit:

Examiner:

For: INTERFERON-GAMMA-BINDING  
MOLECULES FOR TREATING SEPTIC  
SHOCK, CACHEXIA, IMMUNE  
DISEASES AND SKIN DISORDERS

Atty. Dkt. No.: INNS:015/KAM

Int'l Application No. PCT/EP98/05165

Int'l Filing Date: August 14, 1998

ELECTION UNDER 37 C.F.R. §§ 3.71 and 3.73  
AND POWER OF ATTORNEY

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The undersigned, being Assignee of the entire interest in the above-identified application by virtue of an Assignment as set forth below, hereby elects, under 37 C.F.R. § 3.71, to prosecute the application to the exclusion of the inventors.

The Assignee hereby revokes any previous Powers of Attorney and appoints Patricia A. Kammerer, Reg. No. 29,775; M. Todd Rands, Reg. No. P-46,249; Matthew L. Madsen, Reg. No. P-45,594; M. Suzy Strickland, Reg. No. 45,139; Craig M. Lundell, Reg. No. 30,284; Janelle D. Waack, Reg. No. 36,300, and J. Paul Williamson, Reg. No. 29,600, each an attorney or patent agent with the law firm of ARNOLD, WHITE & DURKEE, as its attorney so long as they remain with such law firm, with full power of substitution and revocation, to prosecute the application, to make alterations and amendments therein, to transact all business in the Patent and Trademark Office in connection therewith, to receive any Letters Patent, and for one year after issuance of such Letters Patent to file any request for a certificate of correction that may be deemed appropriate.

Pursuant to 37 C.F.R. § 3.73, the undersigned has reviewed the evidentiary documents, specifically the Assignment to INNOGENETICS N.V. referenced below, and certifies that to the best of my knowledge and belief, title remains in the name of the Assignee.

Please direct all communications as follows:

Patricia A. Kammerer  
ARNOLD, WHITE & DURKEE  
P. O. Box 4433  
Houston, Texas 77210-4433  
(713) 787-1438

ASSIGNEE: INNOGENETICS N.V.

Date: 8/11/2000

By: 

Name: Mr. Rudi Mariën

Title: Managing Director and Chairman of the Board

ASSIGNMENT: Filed Concurrently